N
NXTC
vs
S&P 500
S&P 500
Over the past 12 months, NXTC has underperformed S&P 500, delivering a return of +1% compared to the S&P 500's +14% growth.
Stocks Performance
NXTC vs S&P 500
Performance Gap
NXTC vs S&P 500
Performance By Year
NXTC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
NextCure Inc
Glance View
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 86 full-time employees. The company went IPO on 2019-05-09. Through its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology (FIND-IO), platform, the Company is studying various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Its product candidates include NC318, NC410, NC762 and NC 525. NC318, is an immunomedicine against a novel immunomodulatory protein called Siglec-15. NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor. NC762, is an immunomedicine targeting an immunomodulatory molecule called human B7 homolog 4 protein. NC525, is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia.